487048-28-2

Usage

Uses

Used in Pharmaceutical Synthesis:
N-BOC-CIS-4-CYANO-L-PROLINE METHYL ESTER is used as a building block for the synthesis of pharmaceuticals and other biologically active molecules. Its presence in the molecular structure contributes to the development of drugs with specific therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-BOC-CIS-4-CYANO-L-PROLINE METHYL ESTER is utilized as a chiral catalyst in asymmetric synthesis reactions. Its unique stereochemistry allows for the selective formation of desired enantiomers, which is crucial for the development of effective and safe drugs.
Used in Organic Synthesis:
N-BOC-CIS-4-CYANO-L-PROLINE METHYL ESTER is employed as a reagent in organic synthesis, enabling the preparation of complex molecules with specific functional groups and stereochemistry. Its versatility in chemical reactions makes it a valuable tool for the synthesis of a wide range of organic compounds.
Used in the Preparation of Complex Molecules:
N-BOC-CIS-4-CYANO-L-PROLINE METHYL ESTER is used for the preparation of complex molecules with specific stereochemistry and functional groups. Its unique structure allows for the creation of molecules with tailored properties, making it an essential component in the development of advanced materials and compounds.

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 1256389-46-4 (2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-cyano-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1433280-48-8 [(S)-1-((2S,4S)-4-cyano-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester 
• 1256389-47-5 ((S)-1-{(2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-cyano-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1433281-23-2 ((S)-1-{(2S,4S)-4-carbamoyl-2-[4-(5'-chloro-4'-{[6-((R)-2-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2'-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 
• 1378388-35-2 (3S,5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-pyrrolidine-3-carboxylic acid 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1378389-61-7 (2S,4S)-1-(tert-butoxycarbonyl)-4-((difluoromethoxy)methyl)pyrrolidine-2-carboxylic acid 
• 1377604-63-1 methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-44-6 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1399845-09-0 (2S,4S)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 

Relevant academic research and scientific papers

SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Efficient α-helix induction in a linear peptide chain by n-capping with a bridged-tricyclic diproline analogue

Secondary structure induction: The synthetic tricyclic amino acid ProM-5, which is formally created by stereoselective introduction of a vinylidene bridge into a di-proline unit, acts as a powerful scaffold to nucleate α-helix formation in a linear peptide chain. This might be exploited in the development of new proteomimetics for the modulation of protein interactions. Copyright

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.